索磷布韦联合利巴韦林治疗慢性丙型肝炎的临床观察  

Clinical observation sophobuvir combined with ribavirin in the treatment of chronic hepatitis C

作　　者：赵雪如 赵晨晨 郭婷婷 ZHAO Xueru;ZHAO Chenchen;GUO Tingting(Third Department of Hepatology,Shenyang Sixth People's Hospital,Shenyang,Liaoning,110000,China)

机构地区：[1]沈阳市第六人民医院肝病三科,辽宁沈阳110000

出　　处：《当代医学》2023年第5期162-165,共4页Contemporary Medicine

摘　　要：目的探讨索磷布韦联合利巴韦林治疗慢性丙型肝炎(慢性丙肝)的临床疗效和安全性。方法选取2019年5月至2020年3月本院收治的68例慢性丙肝患者作为研究对象,所有患者均予以索磷布韦联合利巴韦林治疗。统计治疗4、8、12和24周时丙肝病毒(HCV)RNA转阴率及治疗12周时持续病毒学应答(SVR)情况,比较患者治疗前后肝功能、肾功能指标,记录用药期间不良反应发生情况。结果68例慢性丙肝患者治疗4、8、12和24周时HCVRNA转阴率分别为83.82%、91.18%、100.00%、100.00%;治疗12周时SVR率为97.06%。治疗后,患者谷草转氨酶(AST)、谷丙转氨酶(ALT)和总胆红素(TBIL)水平分别为(25.36±3.12)U/L、(22.24±3.07)U/L、(13.25±2.08)μmol/L,均低于治疗前的(99.85±7.69)U/L、(125.34±10.62)U/L、(25.84±4.16)μmol/L,差异有统计学意义(P<0.05)。患者治疗前后尿素氮(BUN)、血尿酸(UA)、尿肌酐(UCr)水平比较差异无统计学意义。患者用药期间不良反应发生率为17.65%,均可耐受,可自行缓解。结论索磷布韦联合利巴韦林可增强慢性丙肝的治疗效果,加快患者HCVRNA转阴,促进肝功能恢复,且对肾功能无明显损害,安全性较高。Objective To investigate the clinical efficacy and safety of sophobuvir combined with ribavirin in the treatment of chronic hepatitis C.Methods A total of 68 patients with chronic hepatitis C admitted to our hospital from May 2019 to March 2020 were selected as the study subjects,all patients were treated with sophobuvir combined with ribavirin.The negative conversion rate of hepatitis C virus(HCV)RNA at 4,8,12 and 24 weeks of treatment and sustained virological response(SVR)at 12 weeks of treatment were statistically analyzed,and the indicators of liver and renal function before and after treatment were compared,the incidence of adverse reactions during the treatment period was recorded.Results At 4,8,12,and 24 weeks of treatment,the negative conversion rates of HCV RNA in 68 patients with chronic hepatitis C were 83.82%,91.18%,100.00%,and 100.00%,respectively;at 12 weeks of treatment,the SVR rate was 97.06%(66/68).After treatment,the levels of aspartate transaminase(AST),alanine transaminase(ALT),and total bilirubin(TBIL)in patients were(25.36±3.12)U/L,(22.24±3.07)U/L,and(13.25±2.08)μmol/L,respectively,which were lower than(99.85±7.69)U/L,(125.34±10.62)U/L,and(25.84±4.16)μmol/L before treatment,the differences were statistically significant(P<0.05).There was no statistically significant difference in the levels of urea nitrogen(BUN),urea nitrogen(UA),and urine creatinine(UCr)before and after treatment.The incidence of adverse reactions during medication was 17.65%,which was tolerable and could be spontaneously alleviated.Conclusion Sophobuvir combined with ribavirin can improve the therapeutic effect of chronic hepatitis C,accelerate the negative conversion of HCV RNA,promote the recovery of liver function,and have no significant damage to renal function,and has high safety.

关 键 词：慢性丙肝 治疗前后 持续病毒学应答 利巴韦林 肾功能指标 转阴率 HCVRNA 尿肌酐 

分 类 号：R512.63[医药卫生—内科学]